Evidence map›Paper›PMID 34020934›Full record

ArticleBMJ open gastroenterology2021

Peritoneal or mesenteric tumours revealing histiocytosis.

Fleur Cohen-Aubart, Irena Ungureanu, Jerome Razanamahery, Frédéric Charlotte, Séverine Valmary-Degano, Zofia Hélias-Rodzewicz, Dominique Cazals-Hatem, Peggy Dartigues, Manuela Delage-Corre, Janick Selves and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 5 countries.

Fleur Cohen-Aubart *Sorbonne University, Paris, Île-de-France, France.ORCID 0000-0002-7610-4995
Irena Ungureanu *Department of Pathology, Hôpital Ambroise-Pare, Boulogne-Billancourt, Île-de-France, France.
Jerome Razanamahery *Department of Internal Medicine and Clinical Immunology, University Hospital Centre Dijon, Dijon, France.ORCID 0000-0001-8453-7224
Frédéric CharlotteDepartment of Pathology, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.
Séverine Valmary-DeganoInstitute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, University Grenoble Alpes, Grenoble, Rhône-Alpes, France.
Zofia Hélias-RodzewiczDepartment of Pathology, Hôpital Ambroise-Pare, Boulogne-Billancourt, Île-de-France, France.
Dominique Cazals-HatemDepartment of Pathology, Hopital Beaujon, Clichy, France.
Peggy DartiguesDepartment of Pathology, Gustave Roussy Institute, Villejuif, Île-de-France, France.
Manuela Delage-CorreDepartment of Pathology, CHU Limoges, Limoges, Limousin, France.
Janick SelvesDepartment of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, Occitanie, France.
Patrick TasDepartment of Pathology, CHU Pontchaillou, Rennes, Bretagne, France.
Sebastien HumbertDepartment of Internal Medicine and Clinical Immunology, University Hospital Centre Dijon, Dijon, France.
Alexandre MalakhiaDepartment of Radiology, University Hospital Centre Besancon, Besancon, France.
Merja KunnamoDepartment of Medicine, Central Finland Central Hospital, Jyvaskyla, Central Finland, Finland.
Liana VeresezanDepartment of Pathology, Centre Henri Becquerel, Rouen, Haute-Normandie, France.
Chrystalla ProkopiouLimassol General Hospital, Lemesos, Cyprus.
Andreas SeeberMedical University of Innsbruck, Innsbruck, Austria.
Abdellatif TaziCentre National de Référence des Histiocytoses, Department of Pneumology, Hospital Saint-Louis, Paris, Île-de-France, France.
Jean DonadieuEA4340-BECCOH, Versailles Saint-Quentin-en-Yvelines University, Versailles, Île-de-France, France.
Olivier LucidarmeDepartment of Radiology, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.
Julien HarocheSorbonne University, Paris, Île-de-France, France.
Jean-François EmileDepartment of Pathology, Hôpital Ambroise-Pare, Boulogne-Billancourt, Île-de-France, France jean-francois.emile@uvsq.fr.ORCID 0000-0002-6073-4466
Université de Versailles Saint-Quentin-en-Yvelines · FRCentre National de la Recherche Scientifique · FRUniversité Sorbonne Nouvelle · FRCentral Finland Health Care District · FICentre Henri BecquerelCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Limoges · FRClinical Emergency Hospital Bucharest · ROHôpital Beaujon · FRHôpital Pontchaillou · FRInnsbruck Medical University · ATInstitut Gustave Roussy · FRInstitut universitaire du cancer de Toulouse Oncopole · FRLimassol General Hospital · CYSorbonne Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePeritoneal or mesenteric tumours may correspond to several tumour types or tumour-like conditions, some of them being represented by histiocytosis. This rare condition often poses diagnostic difficulties that can lead to important time delay in targeted therapies. Our aim was to describe main features of histiocytoses with mesenteric localisation that can improve the diagnostic process.

designWe performed a retrospective study on 22 patients, whose peritoneal/mesenteric biopsies were infiltrated by histiocytes.

resultsAbdominal pain was the revealing symptom in 10 cases, and 19 patients underwent surgical biopsies. The diagnosis of histiocytosis was proposed by initial pathologists in 41% of patients. The other initial diagnoses were inflammation (n=7), sclerosing mesenteritis (n=4) and liposarcoma (n=1). The CD163/CD68+CD1a- histiocytes infiltrated subserosa and/or deeper adipose tissues in 16 and 14 cases, respectively. A

conclusionDiagnosis of masses arising in the mesentery should be carefully explored as one of the possibilities in histiocytosis. This diagnosis is frequently missed on mesenteric biopsies. Molecular biology for detecting the mutations in BRAF or in genes of the MAP kinase pathway is a critical diagnostic tool.

Indexed as

HistiocytosisNeoplasmsDelayed DiagnosisHumansProto-Oncogene Proteins B-rafRetrospective StudiesProto-Oncogene Proteins B-rafabdominal paincancermolecular biology

Identifiers

PMID34020934
PMCPMC8144026
OpenAlexW3160226893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.